Fundamental Analysis of ZYVERSA THERAPEUTICS INC(NASDAQ:ZVSA) stock

Fundamental Rating

Taking everything into account, ZVSA scores 2 out of 10 in our fundamental rating. ZVSA was compared to 561 industry peers in the Biotechnology industry. The financial health of ZVSA is average, but there are quite some concerns on its profitability. ZVSA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ZVSA had negative earnings in the past year.

In the past year ZVSA has reported a negative cash flow from operations.

1.2 Ratios

ZVSA has a worse Return On Assets (-109.81%) than 78.56% of its industry peers.

With a Return On Equity value of -303.53%, ZVSA is not doing good in the industry: 74.95% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-109.81%
ROE	-303.53%
ROIC	N/A

ROA(3y)-406.26%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZVSA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZVSA has more shares outstanding than it did 1 year ago.

ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -10.20, we must say that ZVSA is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -10.20, ZVSA is not doing good in the industry: 74.59% of the companies in the same industry are doing better.

ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.2

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.03 indicates that ZVSA may have some problems paying its short term obligations.

ZVSA has a Current ratio of 0.03. This is amonst the worse of the industry: ZVSA underperforms 99.82% of its industry peers.

ZVSA has a Quick Ratio of 0.03. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.

ZVSA has a worse Quick ratio (0.03) than 99.82% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.03
Quick Ratio	0.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ZVSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.58%, which is quite impressive.

EPS 1Y (TTM)96.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.29%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ZVSA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.94% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y97.53%

EPS Next 2Y41.36%

EPS Next 3Y25.88%

EPS Next 5Y13.94%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZVSA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVSA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ZVSA's earnings are expected to grow with 25.88% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.36%

EPS Next 3Y25.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ZVSA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZYVERSA THERAPEUTICS INC

NASDAQ:ZVSA (1/6/2025, 4:30:02 PM)

1.25

+0.01 (+0.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners5.87%

Inst Owner Change0%

Ins Owners0.2%

Ins Owner Change0%

Market Cap2.92M

Analysts82.5

Price Target71.4 (5612%)

Short Float %1.1%

Short Ratio0.02

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)24.54%

Min EPS beat(2)13.46%

Max EPS beat(2)35.61%

EPS beat(4)2

Avg EPS beat(4)-124.42%

Min EPS beat(4)-526.72%

Max EPS beat(4)35.61%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-11.48%

EPS NY rev (1m)-16.71%

EPS NY rev (3m)-16.71%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.42
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-147.07

EYN/A

EPS(NY)-1.25

Fwd EYN/A

FCF(TTM)-3.9

FCFYN/A

OCF(TTM)-3.9

OCFYN/A

SpS0

BVpS3

TBVpS-4.97

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-109.81%
ROE	-303.53%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-406.26%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.03
Quick Ratio	0.03
Altman-Z	-10.2

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)96.58%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.29%

EPS Next Y97.53%

EPS Next 2Y41.36%

EPS Next 3Y25.88%

EPS Next 5Y13.94%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y46.01%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-438.35%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-438.35%

OCF growth 3YN/A

OCF growth 5YN/A

ZYVERSA THERAPEUTICS INC (ZVSA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens